Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo. Results, presented at PepTalk 2014, demonstrate the ability of Novozymes’ half-life extension platform to prolong the therapeutic half-life of drug candidates, which could potentially reduce the dosing frequency as a result. The technology offers drug developers an attractive approach for optimizing the serum half-life of biopharmaceuticals as well as the possibility for monthly dosing.
By modifying the human albumin molecule, Novozymes managed to alter the affinity of albumin to the FcRn receptor. Extended serum half-life was observed for a range of albumin variants. The platform has the potential to provide patients with better quality of life through tailoring drug circulatory half-life to meet specific medical needs, while improving patient compliance and reducing healthcare costs.